IMPEDIMED LIMITED — AGM Information 2011

Nov 7, 2011

==> picture [781 x 203] intentionally omitted <==

==> picture [272 x 69] intentionally omitted <==

==> picture [272 x 68] intentionally omitted <==

==> picture [272 x 69] intentionally omitted <==

==> picture [272 x 68] intentionally omitted <==

==> picture [272 x 30] intentionally omitted <==

ImpediMed Limited Annual General Meeting

8 November 2011

1

==> picture [781 x 68] intentionally omitted <==

Welcome to the 2011 ImpediMed AGM

==> picture [72 x 37] intentionally omitted <==

• Opening , Welcome & Introductions

• Chairman’s Address – Mr. Mel Bridges/ Dr. Cherrell Hirst

• CEO Presentation – Mr. Greg Brown

• Formal Items of Ordinary Business

• Item 1. To receive and consider Financial Report

• Item 2a. Re-election of Director - Melvyn Bridges

• I te m 2 b . R e e l ect i o n o f Dir ecto r - M a r t in Kri e w a l dt

• Item 3. Remuneration Report

• Item 4. Approval of previous share placement

• Special Business

• Item 5. Approval of issue of options for CEO

• Open Forum

• Conclusion of the Annual General Meeting

==> picture [781 x 68] intentionally omitted <==

2

==> picture [781 x 203] intentionally omitted <==

==> picture [272 x 69] intentionally omitted <==

Chairman’s Address

==> picture [272 x 68] intentionally omitted <==

Dr. Cherrell Hirst

==> picture [272 x 69] intentionally omitted <==

==> picture [781 x 68] intentionally omitted <==

==> picture [272 x 30] intentionally omitted <==

3

==> picture [781 x 68] intentionally omitted <==

Disclaimer

==> picture [72 x 37] intentionally omitted <==

This presentation has been produced by ImpediMed Limited (“ImpediMed”) only and may contain forward-looking statements that are based on management’s current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The forward-looking statements contained in this presentation include statements about future financial and operating results, status of our regulatory submissions, coverage, possible or assumed future growth opportunities and risks and uncertainties that could affect ImpediMed’s product and products under development. These statements are not guarantees of future performance, involve certain risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may not prove accurate. Therefore, actual outcomes and results may differ materially from what is expressed herein. In any forward-looking statement in which ImpediMed expresses an expectation or belief as to future results, such expectation or belief is expressed in good faith and believed to have a reasonable basis , but there can be no assurance that the statement or expectation or belief will result or be achieved or accomplished. We are not under any duty to update forward-looking statements unless required by law.

This investor presentation update is not an offer of the sale of securities.

ImpediMed and their respective directors, employees, associates, affiliates or agents, make no:

• (a) representations or warranties, expressed or implied, in relation to this presentation or the accuracy, reliability or completeness of any information in it or the performance of ImpediMed; and

• (b) accept no responsibility for the accuracy or completeness of this presentation and the information contained in it.

This presentation is intended to provide background information only and does not constitute or form part of an offer of securities or a solicitation or invitation to buy or apply for securities, nor may it or any part of it form the basis of, or be relied on in any connection with any contract or commitment whatsoever. The information in this presentation does not take into account the objectives, financial situation or particular needs of any person. Nothing contained in this presentation constitutes investment, legal, tax or other advice. This presentation does not, and does not purport to, contain all the information prospective investors in ImpediMed would desire or require in reaching an investment decision.

To the maximum extent permitted by law, none of ImpediMed, their officers, directors, employees, associates, affiliates or agents, nor any other person accepts any liability for any loss, claim, damages, costs or expenses of whatever nature (whether or not foreseeable), including, without limitation, any liability arising from fault or negligence on the part of any of them or any other person, for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it or any errors or omissions in it.

The distribution of this presentation in jurisdictions outside Australia may be restricted by law and you should observe any such restrictions. This presentation has not been filed, lodged, registered or approved in any jurisdiction and recipients of this presentation should keep themselves informed of and comply with and observe all applicable legal and regulatory requirements. This presentation is made only to sophisticated or professional investors under the Corporations Act.

4

==> picture [72 x 46] intentionally omitted <==

Board of Directors

==> picture [72 x 37] intentionally omitted <==

==> picture [60 x 27] intentionally omitted <==

Mr Bridges – Non Executive Director

==> picture [60 x 51] intentionally omitted <==

Mr Bridges has over 30 years of international business experience in the healthcare industry. Founder & Chairman of ImpediMed; Chairman of ASX-listed companies Peptech Limited (ASX:PTD) & Alchemia Limited (ASX:ACL); Founder & CEO of Panbio Limited (ASX:PBO); Founder & Managing Director of Pacific Diagnostics, sold to Baxter Corp. in 1986; Winner of national & state awards including the 2005 AusBiotech Chairman’s Industry Medal & 2004 Queensland Entrepreneur of the Year

Cherrell Hirst AO MBBS Best Dune FAICD – Chair

==> picture [61 x 65] intentionally omitted <==

==> picture [60 x 68] intentionally omitted <==

==> picture [60 x 13] intentionally omitted <==

==> picture [60 x 57] intentionally omitted <==

==> picture [60 x 30] intentionally omitted <==

==> picture [60 x 39] intentionally omitted <==

==> picture [60 x 39] intentionally omitted <==

Dr Hirst became a director of the company on the 1st August 2005. Dr Hirst is a medical doctor and until November 2001 was a leading practitioner in the area of breast cancer diagnosis, through which she was involved in women’s health advocacy groups associated with lymphedema. Cherrell Hirst holds Directorships with: Suncorp-Metway Ltd (ASX:SUN); Australian Medical Insurance Limited; Queensland Biocapital Fund; Breast Cancer Network Australia; Biological Committee of the Commonwealth Government Industry Research & Development Board; Queensland Smart State Council; Chancellor of QUT from 1994 to 2004

Martin Kriewaldt BA LLB (Hons) FAICD - Non Executive Director

Martin has expertise in patent, trademark a& intellectual property disputes & in banking & insurance matters, having worked as a partner in litigation for more than 20 years at Allen Allen & Hemsley (now Allen Authur Robinson). Martin Kriewaldt has more than 10 years experience on public Boards; Non-Executive Director, Peptech Limited (ASX:PTD); Non-Executive Director, Suncorp-Metway Ltd (ASX:SUN); Non-Executive Director, Oil Search Limited (ASX: OSH); Non-Executive Director, GWA Intl. Limited (ASX: GWT); Non-Executive Director, Campbell Brothers Limited (ASX:CPB); Chair of IPD Remuneration committee.

Michael Panaccio Bsc (Hons), MBA, PhD FAICD - Non-Executive Director

Co-Founder and Investment Principal of Starfish Ventures; Chairman of the Australian Biotechnology Advisory Committee; Director of the Australia Private Equity and Venture Capital Association and a number of technology companies. Experience includes commercially focused research and development with the Veterinary Research Institute, more than 10 years experience developing collaborations with multinational pharmaceutical companies and Rural Industry Funds & 5 years experience with Singapore-based venture capital firm, Nomura/JAFCO Investment (Asia) Limited.

James Hazel B.Ec, F Fin, FAICD - Non Executive Director

Jim Hazel has had an extensive career in banking and investment banking, including as chief general manager of Adelaide Bank Ltd . Until recently he was managing director of an ASX listed retirement village and aged care operation . He is deputy chairman of Elders Rural Bank Limited and chairs both the credit and risk committees. Previous directorships held include the South Australian Government Financing Authority, Tourism SA, Peptech Limited and St Andrews Hospital Inc.

5

==> picture [781 x 68] intentionally omitted <==

Senior Management

==> picture [72 x 37] intentionally omitted <==

==> picture [69 x 19] intentionally omitted <==

==> picture [69 x 68] intentionally omitted <==

Greg Brown – Chief Executive Officer (CEO) – B. App. Sc. / MBA

Greg has been a director since December 2001, and CEO from February 2004. He has over 20 years of international business experience in the healthcare industry based from Australia, Switzerland, England, Germany and the United States. He has held the roles of ‘Sales and Marketing Director ‘for Baxter Diagnostics in the UK; Senior Global Marketing Manager for Roche Molecular Systems (NY) and Vice President, Global Marketing for Digene Corporation (US & UK).

==> picture [66 x 52] intentionally omitted <==

==> picture [66 x 37] intentionally omitted <==

Peggy Brooker – Acting Chief Operating Officer and Chief Financial Officer – CPA

• Partner E&Y LLP in the U. S. & a Principal in E&Y Australia. Served as engagement partner to public & private companies with revenues in excess of $1B. She held senior E&Y positions, both in the U.S. & Australia.

• Peggy has been the CFO of an insurance broker in Los Angeles , & VP , Finance of an aerospace manufacturer . She has run a small ink manufacturing business in Sydney, Australia. Bachelor of Science Degree in Business/Accounting from the USC & is a licensed CPA in the State of California. Member American Institute of Certified Public Accountants (AICPA).

==> picture [57 x 17] intentionally omitted <==

==> picture [57 x 69] intentionally omitted <==

Bill Gearhart - Senior Vice President Sales and Marketing North America

• Has an extensive record in global marketing & corporate development for medical device companies in the radiology, cardiology, & women's health fields. VP, Global Marketing & Corporate Development for SenoRx, Inc., which was successful in the diagnosis & treatment of breast cancer. Bill was responsible for global marketing, product development, clinical education, partnering, technology licensing . Experience includes VP, S & M for Micro Therapeutics, InterVentional Tech & Schneider (Pfizer). Wharton Business school BA; Ross MBA; Juris Doctorate.

==> picture [63 x 50] intentionally omitted <==

==> picture [63 x 37] intentionally omitted <==

Jack Butler - Senior VP Corporate Development

• Jack has held senior roles in Di g ene Cor p oration for 8 y ears , Roche Dia g nostics US for 12 y ears where he was awarded four President awards for achievement for Roche USA. Jack has 20+years in US sales, managed care and marketing experience.

6

Capital Structure – As at 30 June 2011 Share Price Closed at $0.65 – 7 Nov 2011

==> picture [72 x 46] intentionally omitted <==

==> picture [72 x 37] intentionally omitted <==

	1: Source - ImpediMed Annual Report 2011; 2: Performance shares 3:Includesperformanceshareslisted optionsandunlistedoptions 12 Month Share Price Performance (Source -Yahoo Finance)	1: Source - ImpediMed Annual Report 2011; 2: Performance shares 3:Includesperformanceshareslisted optionsandunlistedoptions 12 Month Share Price Performance (Source -Yahoo Finance)	1: Source - ImpediMed Annual Report 2011; 2: Performance shares 3:Includesperformanceshareslisted optionsandunlistedoptions 12 Month Share Price Performance (Source -Yahoo Finance)	1: Source - ImpediMed Annual Report 2011; 2: Performance shares 3:Includesperformanceshareslisted optionsandunlistedoptions 12 Month Share Price Performance (Source -Yahoo Finance)	1: Source - ImpediMed Annual Report 2011; 2: Performance shares 3:Includesperformanceshareslisted optionsandunlistedoptions 12 Month Share Price Performance (Source -Yahoo Finance)	1: Source - ImpediMed Annual Report 2011; 2: Performance shares 3:Includesperformanceshareslisted optionsandunlistedoptions 12 Month Share Price Performance (Source -Yahoo Finance)	1: Source - ImpediMed Annual Report 2011; 2: Performance shares 3:Includesperformanceshareslisted optionsandunlistedoptions 12 Month Share Price Performance (Source -Yahoo Finance)	1: Source - ImpediMed Annual Report 2011; 2: Performance shares 3:Includesperformanceshareslisted optionsandunlistedoptions 12 Month Share Price Performance (Source -Yahoo Finance)
	, Share Price A$0.57 Listed shares in issue (million) 156.5
	Share Price		A$0.57
	Listed shares in issue (million)		156.5
	U li d h ( illi )2 n ste s ares m on		-
	Listed options (million)		12.49
	Unlisted options (million)		7.1
	Undiluted market cap (million)		A$89.2
	Fully diluted market cap (million)3		A$100.37
	Cash and cash equivalents (million)		A$17.9
	Enterprise value (million)		A$71.3
		Source: Bioshares Q1 2011 Q2 2011 Q3 2011 Bioshares Index 3.9% -9.4% -14% Nasdaq Biotech Index 7.3% 6.5% -12.5% BiosharesLareCa Index -3 1% -7 2% -11 3%
		Source: Bioshares		Q1 2011		Q2 2011	Q3 2011
		Bioshares Index		3.9%		-9.4%	-14%
		Nasdaq Biotech Index		7.3%		6.5%	-12.5%
		BiosharesLareCa Index		-3 1%		-7 2%	-11 3%
		**g p **		.		.	.
		ASX 300 Index		1.9%		-5.0%	-13.1%

7

==> picture [781 x 68] intentionally omitted <==

Key achievements over the year

==> picture [72 x 37] intentionally omitted <==

• 1 . U400 FDA clearance for unilateral limbs

• NAPBC Clinical Standard 2.15 – Lymphedema Management and Risk reduction for breast cancer patients

• NLN guideline recommended by NAPBC clinical standard – strongly recommends BIS (L-Dex)

• Avon foundation white paper & Avon press release – supported pre-emptive care and BIS

• Technology specific code – Category III code published July 2010, active from January 1[st] , 2011

• First coverage statement and now 12.2 million covered lives at better than expected payment levels

• Komen (major activist group) sponsored standard of care pilot for Massachusetts account

• US MedScape program - Continuing Medical Education (CME) on early detection/treatment – covered BIS

• 7 , 204 Readers: 608 Oncologists; 3 , 010 Surgeons;1 , 724 Other MDs; Certificates issued: 1 , 697

• Clinical and Health economic model – presented and submitted for publication

• Raised $13.4 million in capital in the year

• Stanford registry – quarterly testing from baseline for 5 years

• GOG contract signed – major clinical trial for bilateral legs

• Australasian Lymphology Association (ALA) recognises the role of BIS in aiding in early detection

• Expanding the IP portfolio - US market – BIA and BIS hurdles for core business

8

==> picture [781 x 203] intentionally omitted <==

==> picture [272 x 69] intentionally omitted <==

CEO’s Address M G B r. reg rown

==> picture [272 x 68] intentionally omitted <==

==> picture [272 x 69] intentionally omitted <==

==> picture [781 x 68] intentionally omitted <==

==> picture [272 x 30] intentionally omitted <==

9

==> picture [781 x 68] intentionally omitted <==

Clinical Assessment of Lymphedema – Strategic Pillars

==> picture [72 x 37] intentionally omitted <==

==> picture [781 x 136] intentionally omitted <==

==> picture [155 x 11] intentionally omitted <==

• High incidence

• U n de r se rv ed / ea rl y Dx

• Early Dx / prevention

• IP hurdles - building

• � First FDA clearance

• Cat III code - technology

==> picture [84 x 15] intentionally omitted <==

• Legislation - WHCRA

• Support and advocacy AVON

• Clinical Standard - NAPBC

==> picture [62 x 47] intentionally omitted <==

==> picture [62 x 19] intentionally omitted <==

First mover advantage and extensive publications plan

• Code, payment and building coverage – critical to drive sales

• Clinical and economic outcomes - modelled

10

==> picture [781 x 68] intentionally omitted <==

Targeting Multiple Fluid Status Markets – total market potential

==> picture [72 x 37] intentionally omitted <==

Lymphoedema market - Arms

Today & Near Term Lymphoedema market - Legs

• Arms - female breast cancer

• Legs - pelvic cancer

• TGA , FDA , and CE cleared

• Price per test target – upto $85

• Est. - US$150m+ annually at $40

==> picture [182 x 54] intentionally omitted <==

• TGA/CE cleared – FDA submitted

• 80% of total market, 70% unilateral

• Est. - US$400m+annually at $40

Fluid Status Fluid Technology Status Marketplatform

Dialysis market

• Final years of IP arrangements

==> picture [182 x 55] intentionally omitted <==

Oedema market

• Venous insufficiency

• Looking to expand IP

• Fluid status in dialysis patients

• Reducing focus temporarily due to limited resources

Future

• Pelvic cancers - differentiation of lymphoedema / oedema

• Looking to expand regulatory & IP

• 20% of over 70 year age group

11

==> picture [781 x 68] intentionally omitted <==

Business Model – Reimbursement Critical to Drive Model

==> picture [72 x 37] intentionally omitted <==

Illustrative Device Economics

Assumptions (based on primary target surgeon)

	Per Test (USD)	� Target list price per test up to US$85 � Clinician enrols 8 new atients er month
Reimbursement¹	$ Up to 400	p p � Quarterly testing over the first three years
Consumables¹	Up to $85
Net Clinic/Surgeon	Up to $315	� Builds to annual test volume of 1,152 tests

¹Reimbursement and consumable amounts are targets - indicative only

• Device placed in clinicians office, revenue from consumables (electrodes) - per test pricing

• Approximately 250 surgeons treat 20% of all breast cancer patients

• Top 2,000 US surgeons treat approximately 60% of patients

• IPD est. around 800 US surgeons treat around 40% to 45% of all patients – primary target

• IPD est. up to 8000 US surgeons operate on the Breast – Radiation/Oncology accounts can service

12

==> picture [781 x 68] intentionally omitted <==

Reimbursement – Critical to drive business model

==> picture [72 x 37] intentionally omitted <==

1. Coding

==> picture [184 x 131] intentionally omitted <==

----- Start of picture text -----

Coding Coverage
Payment
----- End of picture text -----

• CPT procedure codes

• ICD-9-CM diagnosis and procedure codes

• HCPCS drug, device and durable medical equipment codes

2. Coverage

• National vs. Regional vs. Local coverage policies

• Blue Cross and Blue Shield Technology policies

• Private insurers (National/Regional) and managed care coverage policies

3. Payment

• Outpatient hospital Ambulatory Payment Classification (APC) and pass-through payment

• Physician & diagnostic test payment under the resource-based, relative value schedule (RBRVS)

• Market metrics for showing effective reimbursement – coding, payment and coverage

• The best metric is sales - moving forward placements and revenue per placement important

• Earl y with a new code it is useful to have a metric to show traction, the o p tions are

  • Medical policy – covered lives

    • Medical policy - no policy, experimental/investigational, or medically necessary

    • Less likely to double count lives, but can underestimate coverage

    • Coverage can still occur without medical policy

  • Managed Care – Membership – can show coverage without policy, can double counts lives

13

==> picture [781 x 68] intentionally omitted <==

Reimbursement – Medical necessity definition

==> picture [72 x 37] intentionally omitted <==

A typ ca examp e o a contractua i l l f l d e fi n t on o i i f “ me di ca necess ty l i ” i s as o f ll ows: Services, drugs, supplies or equipment provided by a hospital or other covered provider are:

1. Appropriate to prevent, diagnose, or treat your condition, illness or injury;

2. Consistent with standards of good medical practice in the United States;

3. Not primarily for the personal comfort or convenience of the patient, the family or the provider;

4. Not part of or associated with scholastic education or vocational training or the patient; and

5. In the case of inpatient care, can only be provided safely in the acute inpatient hospital setting.

Criteria 1, 2 and 3 above are most relevant for the purposes of the L-Dex U400.

Two major events occurred within the last 6 months to help establish Medical Necessity:

1. US Clinical standard (NAPBC/NLN) - important for building support for criteria number 2

2. Avon Foundation – recognising pre-emptive care as new standard and supported L-Dex

==> picture [781 x 68] intentionally omitted <==

14

==> picture [781 x 68] intentionally omitted <==

Reimbursement Update

==> picture [72 x 37] intentionally omitted <==

1. L-Dex testing coverage building in the market

• ’

• � – Coverage occurring Explanation of Benefits (EOB s) showing reimbursement of CPT 0239T

• Examples of major private payers covering at local levels - only seen in certain states at present

• Payment in the range supported by the economic model presented in 2010

2. Covered lives metric - medical policy

• 12.2 million covered lives announced – federal and GPA

• Advancing private payers – UPMC, BCBS’s, Humana, TPA’s

• Beginning appeals process – WHCRA / NAPBC / AVON

3. Membership metric - managed Care

• 5 PPO signed contracts in place for handling reimbursement claims

• Beech Street – Viant (BSV) – covering some claims

• BSV is an at risk PPO with 16 million members - Covering L - Dex clients at a percentage of billed charges or contracted default percentage discount when billing CPT 0239T

4. Key obstacles for building covered lives – medical policy

• Need clinical outcomes data for L - Dex over present conventional methods – key to health economics

• Key 5 year data – due December 2011

• A number of surgeons are coordinating to publish outcomes data

• Randomised control trial underway to water displacement

• Medical Directors - clear lack of understanding to the limitations of conventional methods

• Referenced arguments listed on website; Red Journal article in October

15

==> picture [781 x 68] intentionally omitted <==

Review of other recent progress

==> picture [72 x 37] intentionally omitted <==

1. FDA clearance for Unilateral limbs – significant expansion of claims

2. Placement Update

• 162 L-Dex devices placed in the market - July 2011 total was 142 – increase of 20

3. NAPBC/NLN – Clinical Standard 2.15 – First clinical standard/guidelines

4. Avon Foundation for Women Lymphedema event in NYC – supported by Avon, LRF, NLN

• White paper published - calls for more clinical guidelines from governing societies

• � Avon Press release called pre-emptive care as standard of care/supported BIS

5. Prom neni t Clin cai l Centers now us ngi

• UPMC Pittsburg /Columbia Presbyterian Hospital NYC

• William Beaumont Hospital – significant percentage of all breast patients in Michigan

• � Lynn Regional Miami – large breast cancer clinic in Florida

6. Multi-site Users

• 21[st] Century Oncology – expanding placements

7. Stanford registry progressing and on timeline

8. Several key clinical study findings and publications expected

9. Australasian Lymphology Association (ALA) recognises the role of BIS in aiding in early detection

10. Progressing code application for Australia

11. Key trials set up for the UK; France; and Germany

16

==> picture [781 x 68] intentionally omitted <==

Publications plan

==> picture [72 x 37] intentionally omitted <==

1. Lymphedema Review accepted - Int J Radiat Oncolo Biol Phys.

2. Breast-Cancer Related Lymphedema: A Review of Procedure-Specific Incidence Rates, Clinical Assessment Aids, Treatment Paradigms, and Risk Reduction Strategies

3. Lymphedema: Long Review- in the 'Breast' Journal.

4. Breast-Cancer Related Lymphedema: A Review of Procedure-Specific Incidence Rates, Clinical Assessment Aids, Treatment Paradigms, and Risk Reduction Strategies - TBJ-00308-2011, The Breast Journal

5. Short Version - Lymphedema Clinic experience: “Developing a Breast-Cancer Related Lymphedema Program: The William Beaumont Hospital Experience . Accepted in the " Breast ' journal .

6. "Comparison of Lymphedema in Patients with Axillary Lymph Node Dissections (ALND) to those with Sentinel Lymph Node Biopsy (SLNB) followed by Immediate and Delayed ALND". American Journal Clinical Oncology

7. 6 . Long version - Developing a Breast - Cancer Related Lymphedema Program: The William Beaumont Hospital Experience. Journal of Lymphedema.

8. Risk factors for the Development of Lymphedema after BCT - Factors Associated with the Development of Breast-Cancer Related Lymphedema Following Whole Breast Irradiation Therapy – Red Journal

9. “Implementation of a Breast Cancer-related Lymphedema Management Program ” in the category “Resident”. RSNA Trainee Research Prize 2011. Chirag Shah, MD, William Beaumont Hospital, Royal Oak, Michigan. Manuscript to be submitted for publication in Radiology , RadioGraphics , or Medical Physics

17

==> picture [781 x 68] intentionally omitted <==

==> picture [72 x 37] intentionally omitted <==

Next generation technology - UB500 GOG trial

==> picture [205 x 30] intentionally omitted <==

==> picture [313 x 30] intentionally omitted <==

==> picture [781 x 338] intentionally omitted <==

==> picture [263 x 63] intentionally omitted <==

==> picture [313 x 60] intentionally omitted <==

18

==> picture [781 x 68] intentionally omitted <==

	Milestone table – Calender year 2011 / 2012	Milestone table – Calender year 2011 / 2012	Milestone table – Calender year 2011 / 2012	Milestone table – Calender year 2011 / 2012	Milestone table – Calender year 2011 / 2012	Milestone table – Calender year 2011 / 2012	Milestone table – Calender year 2011 / 2012	Milestone table – Calender year 2011 / 2012	Milestone table – Calender year 2011 / 2012
	News Flow Pipeline:	1H11	2H11			1H12		2H12
	Announcement of first covered lives
	Announcement of 20millioncoveredlives
	Stanford registry launch and roll out
	Publication on health economic paper
	Announcement clinical guidelines
	Announcement of 50 million covered lives
	Key outcomes publication on BIS
	Unilateral Limb (arm & leg) FDA - U400
	250 placement of L-Dex devices
	NCD CED Stanford resubmission

19

==> picture [781 x 68] intentionally omitted <==

ImpediMed AGM

==> picture [72 x 37] intentionally omitted <==

• Questions on:

• Financial Report

• Directors’ Report ’

• � I n d d ent u A di R epen tor s eport

==> picture [781 x 136] intentionally omitted <==

20

ImpediMed AGM Ordinary Business – Item 1: Annual Financial Report

==> picture [72 x 46] intentionally omitted <==

==> picture [72 x 37] intentionally omitted <==

Receive and consider the financial report of the Company and the reports of the Directors and the Auditor for the year ended 30 June 2011 which were provided in the Annual Report

==> picture [781 x 203] intentionally omitted <==

21

==> picture [781 x 68] intentionally omitted <==

ImpediMed AGM

==> picture [72 x 37] intentionally omitted <==

• Proxies Received

• Total Number of Valid Proxies Lodged: 68

� 52 185 395 shares Representing: , ,

==> picture [781 x 136] intentionally omitted <==

22

ImpediMed AGM Ordinary Business – Item 2: Election of Directors

==> picture [72 x 46] intentionally omitted <==

==> picture [72 x 37] intentionally omitted <==

T o cons id er an d if th ht fit t th e o f ll i l ti ons as , oug , o pass ow ng reso u : ordinary resolution

• Resolution 2a

• Th a t M e vyn r l B id ges, a Di rec or re t ti r ng y ro a i b t ti on n accor i d ance w ith ru e l .

• 16.1 of the Constitution and being eligible, be re-elected as a Director

• Proxies – 43,964,753 (28.13% of Issued Capital) � For 42,491,342 shares (96.65%)

• � Against 6 , 546 shares (0 . 01%)

• � Abstain 1,466,865 shares (3.34%)

23

ImpediMed AGM Ordinary Business – Item 2: Election of Directors

==> picture [72 x 46] intentionally omitted <==

==> picture [72 x 37] intentionally omitted <==

T o cons id er an d if th ht fit t th e o f ll i l ti ons as , oug , o pass ow ng reso u : ordinary resolution

• Resolution 2b � Th a t M ar ti n w ewa K i ldt , a Di rec or re t ti r ng y ro a i b t ti on n accor i d ance w ith rule 16.1 of the Constitution and being eligible, be re-elected as a Director.

• Proxies – 43,964,753 (28.13% of Issued Capital) � For 42,461,342 shares (96.58%)

• � Against 6 , 546 shares (0 . 01%)

• � Abstain 1,496,865 shares (3.40%)

24

ImpediMed AGM Ordinary Business – Item 3: Remuneration Report

==> picture [72 x 46] intentionally omitted <==

==> picture [72 x 37] intentionally omitted <==

T o cons id er an d if th ht fit t th e o f ll i l ti ons as , oug , o pass ow ng reso u an advisory only resolution:

• Resolution 3 � Th a t th e emunera R ti on epor R t f or th e year en di ng 30 J une 2011 b e adopted.

• Proxies – 42,385,924 (27.12% of Issued Capital) � For 40,624,519 shares (95.84%)

• � A ga ns i t 301 , 512 s h ares (0 . 71%)

• � Abstain 1,459,893 shares (3.44%)

25

ImpediMed AGM Special Business – Item 4: Approval of Previous Share Placement

==> picture [72 x 46] intentionally omitted <==

==> picture [72 x 37] intentionally omitted <==

T o cons id er an d if th ht fit t th e o f ll i l ti ons as , oug , o pass ow ng reso u an : ordinary resolution

• Resolution 4

• That, for all purposes, Members approve the issue of 14,300,000 Shares to the parties, for the purposes and on the terms set out in the Explanatory Statement.

The above resolution has been proposed to satisfy the requirements of Listing Rule 7.4. The Explanatory Statement sets out the information required under Listing Rule 7.5.

• Proxies – 7,559,475 (4.84% of Issued Capital) � For 6,492,635 shares (85.89%)

• � Against 50 , 805 shares (0 . 67%)

• � Abstain 1,016,035 shares (13.44%)

26

ImpediMed AGM Special Business – Item 5: Approval of Issue of Options for Greg Brown

T o cons id er an d if th ht fit t th e o f ll i l ti ons as , oug , o pass ow ng reso u an : ordinary resolution

� Resolution 5

• That, for all purposes, Members approve the issue to Greg Brown, Managing Director and Chief Executive Officer of the Com p an y, of 230 , 000 o p tions , the terms and conditions of which are summarised in the Explanatory Memorandum.

The above resolution has been ro osed to satisf the re uirements of Listin Rule p p y q g 10.11 and the Explanatory Memorandum sets out the information required under Listing Rule 10.13.

• Proxies – 42,586,696 (27.25% of Issued Capital) � For 39,062,168 shares (91.72%)

• � Against 2 , 064 , 635 shares (4 . 85%)

• � Abstain 1,459,893 shares (3.43%)

27

ImpediMed AGM General Business

==> picture [72 x 46] intentionally omitted <==

==> picture [72 x 37] intentionally omitted <==

� General Business:

� Questions to be directed to the Board

==> picture [781 x 203] intentionally omitted <==

28

==> picture [781 x 68] intentionally omitted <==

ImpediMed AGM

==> picture [72 x 37] intentionally omitted <==

==> picture [781 x 68] intentionally omitted <==

Closure of the Meeting

==> picture [781 x 203] intentionally omitted <==

29